Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
10.1186/s40880-016-0163-6
- Author:
Hong SHAODONG
1
;
Zhang LI
Author Information
1. Department of Medical Oncology
- Keywords:
Metastasis;
Nasopharyngeal carcinoma;
Chemotherapy
- From:Chinese Journal of Cancer
2016;35(12):645-646
- CountryChina
- Language:Chinese
-
Abstract:
For decades, the selection of chemotherapeutic regimens for the treatment of recurrent or metastatic nasopharyn-geal carcinoma has been mainly empirical. To our knowledge, there is no phase 3 trial that has been conducted to determine the optimal treatment for these patients before our publication. Recently, we published an article inThe Lancet entitled “Gemcitabine plus cisplatin versus lfuorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.” The results of our study indicate that gemcitabine plus cisplatin could improve the survival of patients with recurrent or metastatic nasopharyngeal carcinoma com-pared with conventional lfuorouracil plus cisplatin.
